Literature DB >> 30009831

CXCL5 as Regulator of Neutrophil Function in Cutaneous Melanoma.

Agnes Forsthuber1, Katharina Lipp1, Liisa Andersen2, Stefanie Ebersberger3, 'Osvaldo Graña-Castro4, Wilfried Ellmeier2, Peter Petzelbauer5, Beate M Lichtenberger1, Robert Loewe6.   

Abstract

Chemokines mold the tumor microenvironment by recruiting distinct immune cell populations, thereby strongly influencing disease progression. Previously, we showed that CXCL5 expression is upregulated in advanced stages of primary melanomas, which correlates with the presence of neutrophils in the tumor. The analysis of neutrophil populations in various tissues revealed a distinct phenotype of tumor-associated neutrophils. Tumor-associated neutrophils expressed PD-L1, CXCR4, CCR5, Adam17, and Nos2 and were immunosuppressive in a T-cell proliferation assay. To investigate the impact of CXCL5 and neutrophils in vivo, we established a syngeneic mouse tumor transplantation model using CXCL5-overexpressing and control melanoma cell lines. Growth behavior or vascularization of primary tumors was not affected by CXCL5 expression and neutrophils alone. However, in combination with Poly(I:C), tumor-associated neutrophils were able to attenuate induced antitumoral T-cell responses. CXCL5-overexpressing tumors had reduced lung metastasis compared with control tumors. Neutrophil depletion reversed this effect. In vitro, unstimulated lung-derived neutrophils had higher levels of reactive oxygen species compared with tumor-associated neutrophils, and CXCL5 stimulation further increased reactive oxygen species levels. In summary, in melanoma, neutrophils play a context-dependent role that is influenced by local or systemic factors, and interfere with therapies activating the acquired immune system. Actively switching neutrophils into antitumorigenic mode might be a new therapeutic strategy.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30009831     DOI: 10.1016/j.jid.2018.07.006

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  16 in total

1.  Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy.

Authors:  Nicholas C DeVito; Michael Sturdivant; Balamayooran Thievanthiran; Christine Xiao; Michael P Plebanek; April K S Salama; Georgia M Beasley; Alisha Holtzhausen; Veronica Novotny-Diermayr; John H Strickler; Brent A Hanks
Journal:  Cell Rep       Date:  2021-05-04       Impact factor: 9.423

2.  Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5.

Authors:  Ziqian Li; Jiawang Zhou; Junjie Zhang; Shiying Li; Hongsheng Wang; Jun Du
Journal:  Int J Cancer       Date:  2019-04-06       Impact factor: 7.396

3.  Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma.

Authors:  Kayo Tanita; Taku Fujimura; Yota Sato; Chunbing Lyu; Yumi Kambayashi; Dai Ogata; Satoshi Fukushima; Azusa Miyashita; Hideki Nakajima; Motoki Nakamura; Akimichi Morita; Setsuya Aiba
Journal:  Front Oncol       Date:  2019-09-20       Impact factor: 6.244

4.  High expression level of peptidylprolyl isomerase A is correlated with poor prognosis of liver hepatocellular carcinoma.

Authors:  Shilong Wang; Minghuan Li; Ligang Xing; Jinming Yu
Journal:  Oncol Lett       Date:  2019-09-10       Impact factor: 2.967

Review 5.  Role of the Neutrophil in the Pathogenesis of Advanced Cancer and Impaired Responsiveness to Therapy.

Authors:  Bernardo L Rapoport; Helen C Steel; Annette J Theron; Teresa Smit; Ronald Anderson
Journal:  Molecules       Date:  2020-04-01       Impact factor: 4.411

Review 6.  Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors.

Authors:  Min Liu; Qian Sun; Feng Wei; Xiubao Ren
Journal:  Cancer Biol Med       Date:  2020-08-15       Impact factor: 4.248

Review 7.  Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers.

Authors:  Taku Fujimura; Setsuya Aiba
Journal:  Biomolecules       Date:  2020-07-22

8.  Immune profile of the tumor microenvironment and the identification of a four-gene signature for lung adenocarcinoma.

Authors:  Tao Fan; Mingchuang Zhu; Liyu Wang; Yu Liu; He Tian; Yujia Zheng; Fengwei Tan; Nan Sun; Chunxiang Li; Jie He
Journal:  Aging (Albany NY)       Date:  2020-12-09       Impact factor: 5.682

9.  CXCL5/NF-κB Pathway as a Therapeutic Target in Hepatocellular Carcinoma Treatment.

Authors:  Xingqing Jia; Shuangqin Wei; Wujun Xiong
Journal:  J Oncol       Date:  2021-05-31       Impact factor: 4.375

Review 10.  CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target.

Authors:  Wen Zhang; Huishan Wang; Mingyang Sun; Xueting Deng; Xueru Wu; Yilan Ma; Mengjing Li; Said Maisam Shuoa; Qiang You; Lin Miao
Journal:  Cancer Commun (Lond)       Date:  2020-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.